

Meeting Host: Enrique Conterno

Senior Vice President, Lilly
Diabetes

President, Lilly USA

B.S. Mechanical Engineering, Case
Western Reserve University

M.B.A., Duke University





**Annual Meeting of the Council to Advance Human Health
(CAHH)**

Innovation and Infrastructure Across Northeast Ohio

Mark Chance, PhD

Vice Dean for Research
School of Medicine

October 8, 2018

- Funds are used to support lead optimization and pre-clinical development in promising drug programs
- CAHH also provides “diligence engine” of alumni experts who advise and advocate for programs
- All projects are thoroughly vetted before funding

accelerator FUND

CASE WESTERN RESERVE UNIVERSITY
SCHOOL OF MEDICINE

Accelerator Fund Supplies Resources for CAHH Sponsored Initial
Development

Office of Translation and Innovation



Mark Chance



Anne DeChant



Blair Geho



Daria Fedyukina



Bill Harte



Steve Fening



Michael Haag



**Stephanie
Weidenbecher**



Ofer Reizes



Translational funding programs de-risk assets

CAHH NCAI TMU CTSC CCTRP OTF/CTF

Translational Funding Opportunities

Vetting Projects

Pilot Funding

Project
Management

Office of Translation and Innovation

- **Training and educating:** providing mentoring and internship experiences for all
 - Building a pipeline of entrepreneurship
 - Regional and national training programs
- **Building technology teams:** bringing together expert investigators and business leaders
 - Vetting programs with industry experts
 - Providing pilot funding to explore new technologies
 - Connecting with incubator and business experts in Northeast Ohio (BioEnterprise, JumpStart, REDIzone)
- **Growing the innovation ecosystem:** expanding physical infrastructure and accelerating spin-outs
 - High-throughput screening and medicinal chemistry facilities expanding at CWRU and CCF
 - New and expanded incubator spaces



CTSC: Translational Workforce Development

Provide translational and clinical workforce training and education opportunities

- Expand CWRU Venture Mentor Program
- Provide internship experience to Ph.D. and Master's students
- Provide on-site events and programming at affiliate hospitals
- Connect with iCorps, C3i and other state and national training programs



- Mentoring CWRU entrepreneurs in developing ventures for biotech related discoveries
- Team mentoring from local industry experts focused on translational research and transitioning projects to industry or clinic
- Creates safe, confidential space

CWRU Venture Mentor Program


- Internship & career exposure provides career guidance, mentorship, exposure to various work environments, new skills and techniques
- Opportunities in special projects, shadowing, volunteer, immersive and traditional
- Consulting, Education, Industry, Non-Profit, etc.

Enhancing Research and Industry Career Horizons



Building Teams

**Protein and RNA therapeutics for
the treatment of lung diseases**



John Tilton, MD
Mitch Drumm, PhD
Jeff Coller, PhD

**Developing GPT2-Specific Inhibitors to Target
PIK3CA Mutant Colorectal Cancer**



John Wang, PhD
Drew Adams, PhD

Convelo Therapeutics, Inc.



Paul Tesar, PhD
Drew Adams, PhD
Brad Lang, PhD

Evotec: Unique disease expertise coming together

Global footprint – Evotec's centres of excellence



Hamburg (HQ), Göttingen, Munich (Germany)

~520 employees

- Hit identification
- *In vitro* & *in vivo* biology
- Chemical proteomics and Biomarker discovery and validation
- Cell & protein production
- Antibody discovery

Abingdon, Alderley Park (UK)

~650 employees

- Medicinal chemistry
- ADME-Tox, DMPK
- Structural biology
- *In vitro* & *in vivo* anti-infective platform
- Process development
- CMC and Commercial manufacture
- Pre-formulation

Toulouse + Lyon (France)

~470 employees

- Compound management
- Hit identification
- *In vitro* & *in vivo* oncology
- Medicinal chemistry
- ADME & PK
- Cell, protein & antibody production
- Anti-infective platform

Verona (Italy), Basel (CH)

~610 employees

- Hit identification
- *In vitro* & *in vivo* biology
- Medicinal Chemistry
- ADME-Tox, DMPK
- Biomarker discovery and validation
- INDiGO
- CMC
- *In vitro* & *in vivo* anti-infective platform

Princeton, Watertown, Branford (USA)

~110 employees


- Compound ID, selection and acquisition
- Compound QC, storage and distribution
- Cell & protein production
- ADME-Tox, DMPK



SCIENCE

Building BRIDGES over the “valley of death”

Evotec's unique model to de-risk early stage science



Innovation is academic curiosity with efficient tools

From idea to PDC based on variable costs



Identification of new mechanisms and lead target ideas

Screening, lead optimisation, PDC development

Drug development



Three successful BRIDGE partnerships




Evotec is execution partner – early stage de-risking and value creation



Oxford Science Innovation (OSI)



MaRS Innovation



- University to provide projects to create spin-outs
- University and/or Funding Partner to fund scouting efforts
- Funding partner to fund specific work plans
- EVT scientists to build work plans and run projects with University scientists
- All 3 parties to participate in NewCo formation via equity

Summary

- Supporting translational projects across the pipeline
 - Funding opportunities
 - Industry vetting and feedback
 - Project management support
- Training and supporting entrepreneurship
 - Mentorship and internship opportunities
 - Regional and statewide training programs
 - Expanded infrastructure across Northeast Ohio for spin-outs